# pleural mesothelioma stages

National Comprehensive Cancer Network - Home » The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 33 leading cancer centers devoted to patient care, research, and education, is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so that patients can live better lives. NCCN offers a number of programs to give clinicians access to tools and knowledge that can help guide decision-making in the management of cancer. Nccn.org

Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma » Intrapleural interleukin-2 for the treatment of patients with malignant pleural mesothelioma is well tolerated, efficient, and results in prolonged survival. Acsjournals.onlinelibrary.wiley.com

Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma | Oncotarget » https://doi.org/10.18632/oncotarget.27010 Marissa Williams, Yuen Yee Cheng, Michaela B. Kirschner, Kadir H. Sarun, Karin Schelch, Patrick Winata, Brian McCaughan, Steven Kao, Nico Van Zandwijk, Glen… Oncotarget.com

Site-Specific Data Item Recodes » Coding scheme for site-specific data item recodes. Seer.cancer.gov

Perioperative Treatment Strategies in EGFR-Mutant Early-Stage NSCLC: Current Evidence and Future Challenges » Treatment with 3 years of adjuvant osimertinib is considered a new standard in patients with completely resected stage I to IIIA NSCLC harboring a common sensitizing EGFR mutation. This therapeutic approach significantly prolonged the disease-free survival and the overall survival versus placebo and revealed a significant role in preventing the occurrence of brain metastases. However, many unanswered questions remain, including the optimal duration of this therapy, whether all patients benefit from adjuvant osimertinib, and the role of adjuvant chemotherapy in this population. Jto.org